Literature DB >> 7535930

Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.

Z Gu1, E J Arts, M A Parniak, M A Wainberg.   

Abstract

A lysine-to-arginine substitution at amino acid 65 (K65R) in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is associated with resistance to 2',3'-dideoxycytidine (ddC), 2',3'-dideoxyinosine (ddI), and the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine (3TC). To further characterize the molecular basis of such resistance, we expressed the pp6/p51 heterodimer of wild-type RT, K65R mutated RT, and a doubly mutated (K65R/M184V) RT in Escherichia coli and assessed the characteristics of nucleotide incorporation and chain termination in cell-free reverse transcription reactions in the presence and absence of various nucleoside triphosphate analogs. These reactions employed a HIV RNA template (HIV-PBS) that contained the primer binding sequence (PBS) and the U5 and R regions of HIV-1 genomic RNA and an oligodeoxynucleotide (dPR) complementary to the HIV-1 PBS as primer. The K65R and K65R/M184V RTs showed significantly decreased chain-termination effects during polymerization with the 5'-triphosphates of ddC, 3TC, 2',3'-dideoxyadenosine, and AZT (3'-azido-3'-deoxythymidine) in comparison with wild-type RT. Detailed analysis with ddCTP and wild-type RT revealed that chain termination occurred at all guanines in the RNA template. However, the frequency of dideoxynucleoside triphosphate (ddNTP)-induced chain termination was decreased at certain guanines but not others in reactions catalyzed by K65R RT. Both the K65R mutant RT and wild-type RT had similar processive activity. These results indicate that decreased chain termination of K65R RT in the presence of ddNTPs is consistent with data obtained in viral replication assays.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535930      PMCID: PMC42298          DOI: 10.1073/pnas.92.7.2760

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 2.  Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.

Authors:  R S Goody; B Müller; T Restle
Journal:  FEBS Lett       Date:  1991-10-07       Impact factor: 4.124

3.  Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information.

Authors:  M Zuker; P Stiegler
Journal:  Nucleic Acids Res       Date:  1981-01-10       Impact factor: 16.971

4.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

5.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

6.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

7.  Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

Authors:  S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; S D Kemp; B A Larder
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

8.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

Authors:  Z Gu; Q Gao; X Li; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.

Authors:  Z Gu; R S Fletcher; E J Arts; M A Wainberg; M A Parniak
Journal:  J Biol Chem       Date:  1994-11-11       Impact factor: 5.157

10.  HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA.

Authors:  C Barat; V Lullien; O Schatz; G Keith; M T Nugeyre; F Grüninger-Leitch; F Barré-Sinoussi; S F LeGrice; J L Darlix
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  33 in total

1.  Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

Authors:  J M de Muys; H Gourdeau; N Nguyen-Ba; D L Taylor; P S Ahmed; T Mansour; C Locas; N Richard; M A Wainberg; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mark A Wainberg; Bluma G Brenner; Dan Turner
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

4.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 5.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

Authors:  Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Authors:  Z Gu; X Li; Y Quan; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.

Authors:  R V Srinivas; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.